Clinical trials: Depressive Symptom
Depressive Disorder, Major
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).
- Trial name
- NCT03614156
- Testing
- Rapastinel
- Where
- 52 sites in United States, Hungary and 3 more
- Volunteers
- 363 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major…
- Trial name
- X-NOVA2 (NCT06775379)
- Testing
- Azetukalner
- Where
- 45 sites in United States
- Volunteers
- 450 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Depression
AZD6765 for Treatment Resistant Depression
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
- Trial name
- NCT00491686
- Testing
- AZD6765
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Cancer
BNT001 Digital Therapeutic Feasibility Pilot Study
This single arm phase II trial focused on cancer patients and cancer survivors in the Veterans Health Administration will gather data on feasibility, acceptability, ease of clinical implementation, and preliminary efficacy of…
- Trial name
- NCT04857008
- Testing
- BNT001
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Blue Note Therapeutics
Major Depressive Disorder
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- Trial name
- SUVN-911 (NCT03551288)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Treatment Resistant Depression, Major Depressive Disorder
Clinical Study of GH001 in Depression
The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Depression
- Trial name
- NCT04698603
- Testing
- 5 Methoxy N,N Dimethyltryptamine
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- GH Research Ireland Limited
Major Depressive Disorder \(MDD, Depressive Disorder, Major
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD)
Trial title: A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of Major Depressive Disorder (MDD) …
- Trial name
- NCT06470035
- Testing
- Active VeNS Device
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 170 people
- Sponsor
- Neurovalens Ltd.
Major Depressive Disorder
Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder
The primary objective of this study is to evaluate the safety and efficacy of an electronic cognitive behavioral therapy application (eCBT Mood) compared to a control group consisting of a mood monitoring handheld computer…
- Trial name
- NCT01752608
- Testing
- eCBT Mood
- Where
- 2 sites in United States
- Sponsor
- MindApps
Depression
Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of Psychiatric Electroencephalogram Registry (PEER) Interactive to inform medication prescription in subjects with a…
- Trial name
- SMART-MD (NCT02988076)
- Testing
- PEER Interactive Report
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- MYnd Analytics
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major…
- Trial name
- CLARITY (NCT07484217)
- Testing
- Solriamfetol 150 MG
- Where
- 40 sites in United States
- Volunteers
- 508 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an…
- Trial name
- NCT01582815
- Testing
- JNJ-40411813
- Where
- 26 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 121 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Symptoms, Major Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology
The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of…
- Conditions
- Depressive Symptoms, Major Depressive Disorder, Depression, Cardiology
- Trial name
- NCT05461599
- Testing
- SparkRx Mobile App
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Limbix Health, Inc.
Depressive Disorder, Major Depression
A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder
The purpose of the study is to assess whether treatment with SR58611A can prevent relapse of depressive symptoms in patients with major depressive disorder.
- Trial name
- CALYPSO (NCT00345098)
- Testing
- SR58611A
- Where
- 13 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 704 people
- Sponsor
- Sanofi
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
- Trial name
- NCT00672958
- Testing
- Vortioxetine
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy of SSR149415 in the treatment of Major Depressive Disorder, defined as a change from baseline to visit 7 in the Hamilton Depression Rating Scale.
- Trial name
- LENA (NCT00361491)
- Testing
- SSR149415
- Where
- 7 sites in Argentina, Bulgaria and 5 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Healthy Volunteers, Major Depressive Disorder
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).
- Conditions
- Healthy Volunteers, Major Depressive Disorder, Depression
- Trial name
- NCT05434156
- Testing
- ELE-101
- Where
- 2 sites in United Kingdom
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eleusis Therapeutics
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mental Disorders
Combination Of PAXIL Tablet And Benzodiazepines
This study was designed to assess the efficacy and safety of combination therapy of PAXIL and benzodiazepine anxiolytics. PAXIL Tablet will be administered to patients with depression or depressive episodes who have received…
- Trial name
- NCT00259883
- Testing
- paroxetine
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorder, Sub-syndromal Symptoms
Evaluation of Sub-syndromal Symptoms After Acute Depressive Episode in Bipolar Disorder
The study aims to evaluate: the frequency of subsyndromal symptoms or disorders observed during interepisode phases in bipolar patients, particularly after a depressive episode in which these subsyndromal disorders are the most…
- Trial name
- POLARIS (NCT01663974)
- Where
- 86 sites in France
- Volunteers
- 125 people
- Sponsor
- AstraZeneca